• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in

No 01 2017

Malin Otmani

-

February 1, 2017

Share article on X
Share article on Linkedin

Updated: January 31, 2025, 09:24 am

Published: February 1, 2017

Top stories

Clinical Trials – June 15, 2026

Immunovia announces new performance data

Immunovia has announced new performance data for PancreaSure in support of its upcoming Medicare coverage application.

Acquisition – June 15, 2026

Pelago Bioscience acquires RG Discovery

By combining Pelago Bioscience’s biology-focused capabilities with RG Discovery’s chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization, the company states.

Clinical Trials – June 15, 2026

SynAct announces positive Phase 2b results

SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.

Careers article – June 14, 2026

Hey there: Johnny Mogensen, new Director of NordForsk

Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Clinical Trials - June 15, 2026

Immunovia announces new performance data

Immunovia has announced new performance data for PancreaSure in support of its upcoming Medicare coverage application.

Acquisition - June 15, 2026

Pelago Bioscience acquires RG Discovery

By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization, the company states.

Clinical Trials - June 15, 2026

SynAct announces positive Phase 2b results

SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.

Careers article - June 14, 2026

Hey there: Johnny Mogensen, new Director of NordForsk

Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.

Career choice - June 14, 2026

Postdoc Interview: “Just like in life, there is no single correct path in science”

Lionel Leck's research focuses on pediatric cancer, particularly neuroblastoma – one of the most commonly diagnosed childhood cancers with a poor prognosis.

In a new job - June 12, 2026

Hansa Biopharma appoints VP Business Development

Hansa Biopharma has announced that Fredrik Röök has been appointed as VP Business Development effective August 17.

Agreement - June 12, 2026

Xbrane Biopharma and JOINN Biologics US enter strategic partnership

The two companies have entered into a strategic partnership featuring customized development services for Xdarzane, Xbrane's biosimilar candidate referencing Darzalex (daratumumab).

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.